MDGL compared with ARGX: revenue, margins and what each company keeps, and the suppliers and customers both name

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

ARGXArgenx SE

Mkt capRevenueRevenue

Compare

MDGLMadrigal Pharmaceuticals, Inc.

ARGXArgenx SE

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MDGL

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±10.5%▼−9.83%×0.93

Q1 FY26±9.2%▲+7.42%×0.80

Feb 19 '26±6.2%▼−11.11%×1.79

Nov 4 '25±12.9%▲+7.83%×0.60

ARGX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 22 '26±8.8%▼−1.61%×0.18

= impliedMDGL realized, solidARGX realized, hatchedOne scale, both sides: full bar = 13%× = |realized| ÷ impliedSource: market data

MDGLMadrigal Pharmaceuticals, Inc.

396.06▼−8.14%· post 395.84· delayed

Mkt cap$10.0BRevenue$431MQ3 FY26Revenue$958MFY25

ARGXArgenx SE

875.30▲+0.04%· post 900.85· delayed

After hoursNov 3 '26delayed

Mkt cap$54.1BRevenue—Revenue—

Compare

After hoursNov 3 '26delayed

MDGLMadrigal Pharmaceuticals, Inc.

ARGXArgenx SE

396.06▼−8.14%post 395.84delayed

Price

875.30▲+0.04%post 900.85delayed

$10.0B

Mkt cap

$54.1B

Q3 FY26$431M

Revenue

—

FY25$958M

Revenue

—

MDGL396.06▼−8.14%vsARGX875.30▲+0.04%After hoursNov 3 '26delayed